Formulation | 20mMTris,150mMNaCl,pH7.4 |
Storage | -80°C |
Purity | >95%bySDS-PAGE |
ActivityDetermination | N/A |
ShelfLife(properlystored) | 12months |
Gel | Novex4-12%Bis-Tris |
---|---|
Load | Humanosteonectin,1µgperlane |
Buffer | MOPS |
Standard | SeeBluePlus2;Myosin(191kDa),PhosphorylaseB(97kDa),BSA(64kDa),GlutamicDehydrogenase(51kDa),AlcoholDehydrogenase(39kDa),CarbonicAnhydrase(28kDa),MyoglobinRed(19kDa),Lysozyme(14kDa) |
Osteonectinisanacidic,noncollagenousglycoprotein(Mr=29,000)originallyisolatedfromfetalandadultbovinebonematrix(1-5).InvitrobovineboneosteonectinbindstypeIcollagen,calcium(Kd=3x10-7M)andhydroxyapatite(Kd=8x10-8M)andhasbeenshowntobeapotentinhibitorofhydroxyapatiteseededcrystalgrowth(6).Inthiscontextithasbeensuggestedthatosteonectinmayplayanimportantroleintheregulationofbonemetabolismbybindinghydroxyapatitetocollagen.Recently,proteinshomologoustoosteonectinhavebeenidentifiedinanumberofcelltypes,mostofwhichareassociatedwithextracellularmatrixproduction(7).Theaminoacidsequence(fromCDNAsequences)ofoneoftheseproteins,humanplacentalSPARCisidenticaltohumanboneosteonectin.
Osteonectinhasalsobeenidentifiedasanalphagranulecomponentofhumanplateletsandissecretedduringactivation.Asmallportionofthesecretedosteonectinisexpressedontheplateletcellsurfaceinanactivationdependentmanner(8).Purifiedplateletosteonectinisasinglechainmoleculewhichexhibitsaslightlylargerapparentmolecularweightthanthatofosteonectinderivedfrombone(8).TheNH2-terminalsequencesofplateletandbone-derivedosteonectinareidentical,butthetwoproteinsdifferwithregardtotheextentotglycosylation(8-10).
HumanplateletosteonectinisisolatedfromthrombinactivatedplateletsasdescribedbyKelm,etal.(8).BovineboneosteonectinisisolatedfromdemineralizedbonebythemethodofRombergetal.(2).Bothproteinsaresuppliedin0.02MTris,0.15MNaCl,pH7.4,andshouldbestoredat-80oC.PurityisjudgedbySDS-PAGEanalysis.
Localization | Bone,platelets,plasma(0.9ug/ml)*(5),serum(2.6ug/ml)**(5). | |||||
---|---|---|---|---|---|---|
Modeofaction | Unknown | |||||
Molecularweight | 32,700(humanbone,fromcDNA)(1) 29,000(bovinebone,bysedimentationequilibrium)(3) | |||||
Extinctioncoefficient |
| |||||
Isoelectricpoint | 5.5***(3) | |||||
Structure | Singlechain,NH2terminalacidicdomain,cysteinerichserpinhomologydomain,2EFhanddomains. | |||||
Post-translationalmodifications | Phosphoserine(11) | |||||
Notes | *DeterminedforHumanPlasma **DeterminedforHumanSerum ***DeterminedforBovineBone |
Haemtech生物制药服务(HBS)是一家领先的,符合cGMP要求的QC测试实验室,专门为生产重组和血浆衍生蛋白疗法的生物制药制造商提供分析服务,重点是那些会影响止血系统的药物。HBS使客户能够满足法规和质量测试要求,从而将其候选药物从开发转向商业化。
对生物制药的需求正在增长,并且该行业正在迅速采用外包策略,以作为满足不断升级的监管要求的一种方式。凭借在止血方面的丰富经验,HBS能够很好地协助开发影响凝血系统的药物产品。